Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...
NoviThera is developing a novel anti Monoclonal anti Body treatment. The invention was made by Allan Wehnert, CEO of NoviThera in conjunction with Nordicus. NoviThera’s mission is to research and ...
For adults and adolescents with moderate-to-severe plaque psoriasis, selective blockade of the interleukin-23 receptor with ...
Everyday Health on MSN
7 Psoriasis Myths and the Facts That Debunk Them
Discover key truths about psoriasis, from symptoms and causes to effective management strategies to improve your quality of ...
A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...
Significant rates of depression, anxiety, and sleep disturbances in patients with psoriatic arthritis (PsA) and palmoplantar psoriasis (PPP) were identified, underscoring the need for integrated ...
Hispanic adults with psoriasis receive biologics far less often than non-Hispanic White adults, despite having more prescriptions and more dermatologist visits.
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback